article · Journal of Antimicrobial Chemotherapy
OBJECTIVE: We previously reported a high prevalence of HIV drug resistance mutations (DRMs) among adolescents with a viral load (VL) ≥ 200 copies/mL. In this study, we complement this analysis by simultaneously characterizing circulating and archived viruses in order to obtain a more comprehensive drug resistance profile. METHODS: Using 127 plasma and paired buffy-coat samples collected between February and September 2021 from 90 adolescents (10-19 years) with a VL ≥ 200 copies/mL, we performed genotyping resistance testing on both circulating and archived viral strains using an in-house Sanger method targeting the reverse transcriptase, protease and integrase genes. The Stanford HIValg programme was used to identify relevant DRMs. RESULTS: We generated 97 (76.4%) paired archived and circulating viral sequences, of which 60 (61.9%) were recombinant CRF02_AG. Globally, about 8/10 participants harboured DRMs to at least one drug class in circulant (80.4%) and archived (77.3%) viruses, slightly higher in samples with VL between 200 and 999 copies/mL and mainly NRTIs and NNRTI-associated resistance. One-third of the participants had cross-resistance to the newer NNRTIs rilpivirine and doravirine, which are not yet available in our settings. More than half (56.7%) of the DRMs were detected in both viral populations, but 2-fold more DRMs were found exclusively in circulant strains (29.8% versus 13.4% in archived viruses). CONCLUSION: The high level of resistance found in this study, coupled with the identification of DRMs either in circulating and archived viruses, only suggests that a comprehensive profiling of DRMs in both viral populations would provide additional information for adolescents with a detectable viremia.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1093/jac/dkaf356
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.